Oric Pharmaceuticals (ORIC) announced additional efficacy and safety data from the Phase 1b trial of once-daily ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration-resistant prostate cancer. The company reported a 55% PSA50 response rate and a 20% PSA90 response rate. Rapid and deep ctDNA reductions were observed in 76% of patients. Based on the results, ORIC has selected provisional recommended Phase 2 doses and plans to announce preliminary dose optimization data in Q1 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals Reports Promising ORIC-944 Trial Results
- Oric Pharmaceuticals reports Q3 EPS (33c), consensus (40c)
- Is ORIC a Buy, Before Earnings?
- Promising Preclinical Data and Strategic Combinations Bolster Buy Rating for ORIC-944
- Oric Pharmaceuticals’ Promising Study on ORIC-944 for Metastatic Prostate Cancer